CVS Health (CVS) Panoramica del titolo
CVS Health Corporation fornisce soluzioni sanitarie negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 5/6 |
Premi
Analisi del rischio
CVS Community Fair Values
Create NarrativeSee what 439 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Concorrenti di CVS Health Corporation
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$94.99 |
| Massimo di 52 settimane | US$110.68 |
| Minimo di 52 settimane | US$66.24 |
| Beta | 0.60 |
| Variazione di 1 mese | -10.54% |
| Variazione a 3 mesi | -0.94% |
| Variazione di 1 anno | 42.35% |
| Variazione a 3 anni | 42.20% |
| Variazione a 5 anni | 12.77% |
| Variazione dall'IPO | 14,368.67% |
Notizie e aggiornamenti recenti
Seeking Alpha • Aug 10
CVS Health: I Wanted A Beat And Raise, I Got It, And I'm Still At 'Hold'
Summary CVS Health Corporation's strong Q2 results delivered revenue and earnings beats while management raised operating cash flow guidance to $11.5 billion. Aetna turnaround and improved medical benefit ratios boosted first half cash generation, helping drive recent stock gains. Management anticipates higher second half medical costs alongside 2027 headwinds from 340B pricing and pharmacy drug mix shifts. Strengthening cash flow supports deleveraging and dividend safety, but the recent CVS stock rally keeps the thesis at Hold. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 05
CVS: GLP 1 Expansion And Legal Risks Will Shape Future Earnings
The analyst price target for CVS Health has shifted from $111.92 to $114.88. This change reflects updated views from recent Street research that focuses on valuation, medical loss ratio trends, regulatory clarity, and ongoing growth investments across its healthcare services businesses.Aggiornamento narrativa • Jul 22
CVS: GLP‑1 Expansion And Legal Settlements Will Shape Future Earnings Stability
The analyst price target for CVS Health has been lifted by about $4 to reflect modestly higher fair value estimates around $112. Analysts point to sector tailwinds in healthcare services, expectations for more stable managed care trends, and company-specific growth investments in areas such as GLP-1 support programs and technology.Recent updates
Seeking Alpha • Aug 10
CVS Health: I Wanted A Beat And Raise, I Got It, And I'm Still At 'Hold'
Summary CVS Health Corporation's strong Q2 results delivered revenue and earnings beats while management raised operating cash flow guidance to $11.5 billion. Aetna turnaround and improved medical benefit ratios boosted first half cash generation, helping drive recent stock gains. Management anticipates higher second half medical costs alongside 2027 headwinds from 340B pricing and pharmacy drug mix shifts. Strengthening cash flow supports deleveraging and dividend safety, but the recent CVS stock rally keeps the thesis at Hold. Read the full article on Seeking AlphaAggiornamento narrativa • Aug 05
CVS: GLP 1 Expansion And Legal Risks Will Shape Future Earnings
The analyst price target for CVS Health has shifted from $111.92 to $114.88. This change reflects updated views from recent Street research that focuses on valuation, medical loss ratio trends, regulatory clarity, and ongoing growth investments across its healthcare services businesses.Aggiornamento narrativa • Jul 22
CVS: GLP‑1 Expansion And Legal Settlements Will Shape Future Earnings Stability
The analyst price target for CVS Health has been lifted by about $4 to reflect modestly higher fair value estimates around $112. Analysts point to sector tailwinds in healthcare services, expectations for more stable managed care trends, and company-specific growth investments in areas such as GLP-1 support programs and technology.Aggiornamento narrativa • Jul 08
CVS: GLP‑1 Support And Managed Care Stability Will Shape Future Earnings
The analyst price target for CVS Health has been revised higher to $107.73 from $105.38 as analysts factor in modest adjustments to discount rates, revenue growth, profit margin assumptions, and a slightly higher future P/E multiple, supported by recent sector-wide target increases and company specific developments such as expanded GLP-1 support programs and views of a more stable policy backdrop for managed care. Analyst Commentary Recent research on CVS Health points to a cluster of higher price targets, with analysts focusing on execution in managed care, the impact of GLP-1 support programs, and shifts in policy and utilization assumptions.Aggiornamento narrativa • Jun 24
CVS: Medicare Advantage Margins And GLP‑1 Programs Will Shape Future Earnings
Analysts have raised the implied fair value for CVS Health from about $102.85 to roughly $105.38. This change reflects higher Street price targets tied to expanding GLP-1 support programs, a calmer policy backdrop for managed care, and expectations for steadier earnings power across the business.Aggiornamento narrativa • Jun 03
CVS: Medicare Advantage Margin Recovery Will Shape Future Earnings Profile
Narrative Update Analysts have nudged the CVS Health fair value estimate from $101.58 to $102.85, reflecting a series of higher price targets in the $106 to $110 range as they highlight margin recovery in government businesses, steadier pharmacy and pharmacy benefit manager earnings after reform, and supportive Q1 medical cost trends. Analyst Commentary Recent Street research on CVS Health clusters around a similar message, with several firms lifting price targets into a tighter band and pointing to company specific factors rather than broad sector calls.Articolo di analisi • May 18
Investors Can Find Comfort In CVS Health's (NYSE:CVS) Earnings Quality
CVS Health Corporation's ( NYSE:CVS ) stock was strong despite it releasing a soft earnings report last week. However...Aggiornamento narrativa • May 15
CVS: Medicare Advantage Turnaround And PBM Clarity Will Shape Future Earnings Profile
Analysts have lifted the fair value estimate for CVS Health by $5 to $101.58, reflecting a series of higher price targets around $106 that emphasize expectations for a Medicare Advantage turnaround, steadier pharmacy and pharmacy benefit manager earnings, and reduced regulatory uncertainty after recent PBM reform and Federal Trade Commission actions. Analyst Commentary Recent Street research on CVS Health has become more constructive, with a cluster of higher price targets around $106 and several rating upgrades that feed directly into the higher fair value estimate.Articolo di analisi • May 08
CVS Health Corporation Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
CVS Health Corporation ( NYSE:CVS ) defied analyst predictions to release its quarterly results, which were ahead of...Aggiornamento narrativa • Apr 22
CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Future Earnings
CVS Health's analyst price targets have edged higher by a few dollars, as analysts factor in slightly stronger revenue and margin assumptions, a modestly lower discount rate, and a somewhat lower future P/E multiple in light of recent research that highlights Medicare Advantage exposure, potential earnings stability in pharmacy, and reduced regulatory uncertainty tied to a possible FTC settlement. Analyst Commentary Recent research on CVS Health reflects a mix of cautious optimism and ongoing concern, with analysts adjusting price targets by only a few dollars in either direction as they reassess earnings quality, regulatory risks, and Medicare Advantage exposure.Aggiornamento narrativa • Apr 08
CVS: Medicare Advantage Turnaround Will Support Future Earnings Recovery
Analysts have trimmed the average CVS Health price target by a few dollars to around the mid $90s. This reflects slightly softer revenue growth assumptions, modestly higher margin expectations, and updated views on Medicare Advantage and regulatory risks following recent CMS and FTC related commentary.Aggiornamento narrativa • Mar 25
CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Earnings Recovery
Analysts have slightly raised their fair value estimate for CVS Health to $96.50, citing improving clarity around potential FTC settlements and a perceived Medicare Advantage turnaround. These developments could support a higher future P/E multiple, even with more conservative assumptions for revenue growth and profit margins.Aggiornamento narrativa • Mar 11
CVS: Medicare Advantage Policy And Rates Will Support Future Earnings Recovery
Analysts have adjusted their price targets on CVS Health modestly lower. Our updated fair value estimate has moved from about $94.84 to roughly $96.38 per share.Aggiornamento narrativa • Feb 24
CVS: Medicare Advantage And Great Healthcare Plan Will Support Future Margin Recovery
Analysts have trimmed their average price target on CVS Health by a few dollars, citing updated views on Medicare-related policy risks and a slightly lower future P/E assumption, even as they factor in modestly stronger profit margins over time. Analyst Commentary Recent research on CVS Health reflects a mix of optimism around long term earnings potential and caution around policy and reimbursement risk tied to Medicare and broader health reform proposals.Aggiornamento narrativa • Feb 09
CVS: Medicare Advantage And Great Healthcare Plan Will Drive Earnings Recovery
Analysts have trimmed their fair value estimate for CVS Health by about $0.20 to $94.76, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and updated sector views after recent price target reductions and commentary around Medicare Advantage and managed care rates. Analyst Commentary Recent Street research around CVS Health centers on Medicare Advantage rate visibility, the outlook for managed care earnings, and shifting expectations for health policy.Aggiornamento narrativa • Jan 23
CVS: Medicare Advantage And Great Healthcare Plan Will Support Earnings Rebound
Analysts have nudged their average price targets for CVS Health higher, with increases such as Bernstein moving to $91 from $87, BofA to $100 from $89, and RBC to $93 from $81. These changes reflect views that recent policy developments and Q3 results support a steadier outlook for government managed care earnings and potential catalysts in Medicare Advantage.
Aggiornamento narrativa • Jan 09
CVS Health: Rebuilding a Healthcare Giant From the Inside Out
CVS Health (NYSE: CVS) has not been an easy stock to own. Over the past year, investors have watched margins compress, guidance get revised, and sentiment sour as healthcare cost inflation collided with reimbursement pressure.Aggiornamento narrativa • Jan 08
CVS: Medicare Advantage Margin Recovery From 2026 Will Drive Earnings Rebound
Narrative Update Analysts have raised their blended price target on CVS Health by about $1, citing recent target increases into the low to mid $90s and $100 range. They also note views that Medicare Advantage and broader managed care earnings could enter recovery phases beginning around 2026, despite expected bumps along the way.Aggiornamento narrativa • Dec 23
CVS: Medicare Advantage Margin Recovery Is Expected To Drive Earnings Momentum From 2026
Analysts have modestly raised their price target on CVS Health, with our fair value estimate increasing from approximately $92.44 to $94.33. This reflects growing confidence in earnings visibility, margin recovery in Medicare Advantage, and supportive recent EPS revisions despite mixed near term trends.Aggiornamento narrativa • Dec 09
CVS: Medicare Advantage Margin Recovery Will Drive Earnings Momentum From 2026
The analyst price target for CVS Health has edged higher by about $1 to approximately $92, as analysts point to resilient earnings, improving visibility in Medicare Advantage margins, and a solid Q3 performance as support for modestly stronger long term valuation assumptions. Analyst Commentary Research updates highlight a generally constructive view on CVS Health, with multiple firms lifting price targets and emphasizing improved earnings visibility and margin recovery potential over the medium term.Aggiornamento narrativa • Nov 25
CVS: Margin Recovery in Medicare Advantage Will Drive Earnings Momentum Through 2026
The analyst price target for CVS Health has been revised slightly lower from $91.52 to $91.48. Analysts point to a mixed quarterly report and evolving expectations around Medicare Advantage and earnings visibility as factors behind the update.Aggiornamento narrativa • Nov 08
CVS: Earnings Momentum Will Drive Performance as Regulatory Shifts Unfold
Analysts have raised their fair value estimate for CVS Health to $91.52 from $86.20. This adjustment is due to improved earnings visibility and continued momentum following solid quarterly results.Aggiornamento narrativa • Oct 25
Managed Care Margin Recovery And Healthcare Benefits Will Shape Industry Prospects
Analysts have raised their fair value estimate for CVS Health to $86.20. This modest increase is supported by greater earnings visibility and expectations for margin recovery in the managed care sector.Aggiornamento narrativa • Oct 10
Digital Health Transformation And Integrated Care Will Expand Reach
Analysts have raised their price target for CVS Health, increasing it by nearly $2 to approximately $84 per share. They cite improved earnings visibility and strengthening fundamentals in the healthcare sector as key reasons for the change.Aggiornamento narrativa • Sep 04
Digital Health Transformation And Integrated Care Will Expand Reach
Despite ongoing external risks and policy uncertainty, analysts remain constructive on CVS Health, citing strong recent execution, conservative guidance with potential for upside, and compelling valuation, resulting in the consensus price target holding steady at $81.57. Analyst Commentary Bullish analysts cite strong recent execution and early signs that fixes in the healthcare benefits segment are proving effective, supporting above-consensus earnings growth projections.Seeking Alpha • Mar 30
CVS Health: I Don't Understand The Fuss, But The Worst Is Behind
Summary CVS Health experienced a significant turnaround in 2025, with shares up nearly 50% after a 44% decline in 2024. The recent rally is not driven by great results or strong guidance under new CEO leadership, but rather bad ones that just weren't as terrible as expected. CVS's 2025 outlook includes modest revenue growth, improved operating income, and a focus on stabilizing margins and profitability. Despite uncertainties, CVS's valuation does seem fair considering the worst is seemingly behind, leading to an upgraded rating from 'Sell' to 'Hold'. Read the full article on Seeking AlphaSeeking Alpha • Feb 26
CVS Health: Incremental Improvement Best Hope For 2025 (Rating Downgrade)
Summary CVS Health experienced a significant share price decline in 2024, driven by earnings misses, CEO departure, and regulatory pressures on its PBM and Medicare Advantage businesses. Q4 2024 earnings showed revenue growth but declining operating income and EPS, with the healthcare benefits division facing rising costs and lower profitability. The new CEO aims to improve outcomes, increase access, and lower care costs, but faces challenges such as CMS rate negotiations and activist investor pressures. Despite recent share price gains, I downgrade CVS to "Hold" due to ongoing operational challenges and uncertainties about achieving a turnaround in 2025. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
CVS Health Jumps On Q4 Earnings Beat, But Downgrading To Hold
Summary Despite a >10% rise in CVS Health's stock price from my initial BUY recommendation, CVS Health is downgraded to Hold due to substantial political risks and declining cash flow. CVS faces significant challenges, including DOJ lawsuits, potential business separation, political scrutiny, and declining cash flow, impacting its turnaround prospects. CVS reported strong Q4 sales and new leadership from the new CEO David Joyner may bode well for shareholders. However, political risks and ongoing industry battles make CVS Health's turnaround uncertain, warranting a conservative Hold rating despite the recent rally in its stock price. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
CVS Health Isn't Going To The Dogs
Summary CVS Health's poor 2024 performance was driven by negative macro and micro factors. Investors became too pessimistic about the company's forward prospects. A new CEO is a catalyst. Despite weak 2024 financial results, CVS is likely to begin to rebound in 2025. The company remains free cash flow positive, despite myriad challenges. I believe the cash dividend, now yielding 5 percent, remains safe. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
CVS Health: An Attractive 5.8% Safe Yield For Now
Summary Despite significant headwinds and a 43% stock decline, CVS Health's 5.8% dividend yield remains attractive, with a well-covered payout ratio of 55.9%. CVS faces strong competition from Amazon, Walmart, and Costco, impacting market share and pushing management to revise cash flow guidance down to $9.0 billion. The company saw double-digit revenue growth in two of its three segments, with a slight increase in pharmacy market share to 27.3%. With a potential upside of nearly 45%, CVS could be a compelling buy for patient investors, but I maintain a hold rating due to ongoing uncertainties. Read the full article on Seeking AlphaRendimenti per gli azionisti
| CVS | US Healthcare | US Mercato | |
|---|---|---|---|
| 7D | -1.3% | -0.4% | 1.0% |
| 1Y | 42.3% | 33.7% | 18.4% |
Ritorno vs Industria: CVS ha superato il US Healthcare che ha restituito 33.7 % nell'ultimo anno.
Rendimento vs Mercato: CVS ha superato il mercato US che ha restituito 18.4 % nell'ultimo anno.
Volatilità dei prezzi
| CVS volatility | |
|---|---|
| CVS Average Weekly Movement | 3.8% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: CVS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di CVS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1963 | 259,500 | J. Joyner | www.cvshealth.com |
CVS Health Corporation fornisce soluzioni sanitarie negli Stati Uniti. Il segmento “Health Care Benefits” offre prodotti assicurativi sanitari tradizionali, volontari e orientati al consumatore, nonché servizi correlati, tra cui piani sanitari medici, farmaceutici, odontoiatrici e di salute comportamentale; servizi di gestione medica; piani Medicare Advantage e Medicare Supplement; piani per i farmaci da prescrizione (PDP); e servizi di gestione dell’assistenza sanitaria Medicaid. Si rivolge a gruppi di datori di lavoro, privati, studenti universitari, lavoratori part-time e a ore, piani sanitari, operatori sanitari, enti governativi, piani sponsorizzati dal governo, sindacati ed espatriati.
CVS Health Corporation Riepilogo dei fondamenti
| CVS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$121.14b |
| Utili (TTM) | US$4.89b |
| Ricavi(TTM) | US$412.65b |
24.8x
Rapporto P/E0.3x
Rapporto P/SCVS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| CVS Conto economico (TTM) | |
|---|---|
| Ricavi | US$412.65b |
| Costo del fatturato | US$356.34b |
| Profitto lordo | US$56.31b |
| Altre spese | US$51.42b |
| Utili | US$4.89b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 3.82 |
| Margine lordo | 13.64% |
| Margine di profitto netto | 1.19% |
| Rapporto debito/patrimonio netto | 76.9% |
Come si è comportato CVS nel lungo periodo?
Vedi performance storica e confrontoDividendi
2.8%
Rendimento attuale del dividendo69%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/13 21:55 |
| Prezzo dell'azione a fine giornata | 2026/08/13 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
CVS Health Corporation è coperta da 49 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Harshit Gupta | Accountability Research Corporation |
| Christopher Graja | Argus Research Company |
| Hua Ha | Baird |